If you’re operating on AI-generated research, competitive briefs, or regulatory reasoning that hasn’t been adversarially validated — you’re in the right place. Enterprise inquiries are reviewed personally within 48 hours. Media, partnership, and investor relations welcome.
If your organization is running on AI-generated science — and most are, without knowing it — the right first step is a conversation. We review every submission personally and respond with a direct assessment, not a sales sequence.
corporate@aimwellbio.comNewsroom, analyst briefings, and commentary on regulatory intelligence, biopharma AI, and decision infrastructure.
corporate@aimwellbio.comInstitutional investor relations, strategic partnerships, and board-level inquiries.
corporate@aimwellbio.comContinuous signal ingestion and regulatory monitoring across the major agencies.
Headquarters, operations center, and US-based regulatory & legal infrastructure. FDA CDER / CBER coverage.
EMA continuous monitoring, MHRA post-Brexit coverage, and European institutional client support.
PMDA, NMPA, WHO, and regional regulatory coverage for global pharmaceutical organizations.
Distributed signal ingestion, processing pipelines, and redundancy across multiple regions.
Walk through a live signal capture. Zero sales pressure. 15 minutes.